Skip to main content
main-content

Medicine Matters branded image Welcome

We provide news, expert interviews, and educational resources to help you keep up with the latest developments in diabetes

News

Global variation in optimal BMI, age cutoffs for diabetes screening

Doctor checking patient's blood glucose

Researchers find large geographic differences in the influence of BMI and age on the risk for type 2 diabetes in low- and middle-income countries.

Educational hub

Addressing suicide risk in diabetes

AdobeStock_361457690

Learn about rates and risk, underlying psychological factors, and practical actions to support patients.

ADA 2021 coverage

Browse all of the latest research news, researcher interviews, and independent commentary.

Addressing suicide risk in diabetes

Learn about rates and risk, underlying psychological factors, and practical actions to support patients.

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

MOST WATCHED | Metformin and oral combination therapies

06-29-2021 | ADA 2021 | Conference coverage | Video

GRADE: A head-to-head comparison of four metformin add-ons for type 2 diabetes

Deborah Wexler discusses the findings from GRADE, a head-to-head study comparing glimepiride, sitagliptin, insulin glargine, and liraglutide when used in combination with metformin for the treatment of type 2 diabetes.

The SURPASS trials

Get the latest reporting, researcher interviews, and independent commentary on tirzepatide for type 2 diabetes.

MOST WATCHED | Tirzerpatide & type 2 diabetes

06-27-2021 | ADA 2021 | Conference coverage | Video

SURPASS-3: Tirzepatide versus insulin degludec in type 2 diabetes

Francesco Giorgino discusses the advantages of tirzepatide over insulin degludec revealed in the SURPASS-3 findings for people requiring an injectable therapy for type 2 diabetes.

MOST READ | Cardiovascular disorders

06-29-2021 | ADA 2021 | Conference coverage | News

AMPLITUDE-O: Efpeglenatide offers cardiorenal protection in type 2 diabetes

Efpeglenatide provides significant cardiovascular and renal protection in people with type 2 diabetes at high risk for cardiorenal events, show the findings of the AMPLITUDE-O trial.

MOST READ | GLP-1 receptor agonists

06-26-2021 | ADA 2021 | Conference coverage | News

Tirzepatide has efficacy edge over semaglutide in SURPASS-2

People with type 2 diabetes on metformin monotherapy have greater glycemic control improvement and weight reduction with tirzepatide than semaglutide, report the SURPASS-2 investigators.

Flash glucose monitoring technology

Browse new slide sets summarizing the latest results from real-world studies.

MOST READ | Diabetes devices & technology

06-02-2021 | ATTD 2021 | Conference coverage | News

Studies support wider CGM access in type 2 diabetes

The results of two studies published in JAMA indicate that real-time continuous glucose monitoring benefits people with type 1 or type 2 diabetes on a range of insulin regimens and from a wide variety of backgrounds.

SGLT2 inhibitor use in type 2 diabetes management

Learn about prescribing these medications with guidance from the Improving Diabetes Steering Committee.

  • » A prescribing tool to inform prescribing decisions for SGLT2 inhibitors
  • » SGLT2 inhibitors: Key evidence and implications for clinical practice
  • » Translating SGLT2 inhibitor cardiovascular evidence into practice
  • » This content is intended only for UK healthcare providers and was made possible by educational funding provided by Napp Pharmaceuticals Ltd.

MOST READ | SGLT2 inhibitors

06-10-2021 | Adverse effects | News

Steep eGFR drop on SGLT2 inhibitor initiation may pose cardiorenal risk

The small proportion of people who experience an eGFR fall of more than 30% on starting an SGLT2 inhibitor may be at increased risk for adverse outcomes, research suggests.

Semaglutide for weight loss: The STEP and SELECT trials

Get the latest results and insights from the researchers.

MOST READ | Obesity & lifestyle interventions

07-15-2021 | Epidemiology | News

Global variation in optimal BMI, age cutoffs for diabetes screening

Researchers find large geographic differences in the influence of BMI and age on the risk for type 2 diabetes in low- and middle-income countries.

Podcasts

Interviews with experts on diabetes patient care

Image Credits